Avalyn Pharma Inc.
AVLN
$38.94
$2.366.45%
NASDAQ
| 06/30/2026 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -7.69% | -15.36% | |||
| Total Depreciation and Amortization | 74.60% | -10.00% | |||
| Total Amortization of Deferred Charges | 240.00% | -- | |||
| Total Other Non-Cash Items | 155.59% | 4,480.00% | |||
| Change in Net Operating Assets | 100.24% | 33.67% | |||
| Cash from Operations | 12.76% | -7.38% | |||
| Capital Expenditure | 15.41% | 100.00% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -314.02% | -252.05% | |||
| Cash from Investing | -315.74% | -252.10% | |||
| Total Debt Issued | -100.00% | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | 1,283,316.00% | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -2,465.03% | -- | |||
| Cash from Financing | 2,030.76% | -- | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 329.77% | 570.97% | |||